Objectives. This study aimed to estimate the responsiveness to change of a generic [the 36-item Short Form Health Survey (SF-36)] and a specific health-related quality of life questionnaire [the Lupus Quality if Life questionnaire (LupusQoL)] according to SLE patients' self-reported changes in health status.
Introduction SLE is a rare systemic autoimmune disease with a recently estimated prevalence in France of 43/100 000 [1] . Given the constant improvement in life expectancy of SLE patients [2] , the long-term impact of the disease, including physical damage, social burden and psychological impact, must be considered [3] in order to improve their quality of life (QoL). To respond to this need, generic health-related QoL (HRQoL) questionnaires have been widely used in past decades [4] . In addition, SLE-specific HRQoL questionnaires have recently been developed [59] . It has been suggested that disease-specific questionnaires would be more pertinent and sensitive to changes in disease status because of the inclusion of SLE-specific problems such as sleep, body image and sexual disorders [10] . Moreover, specifying problems as 'because of my lupus' in the specific questionnaires helps to focus on problems perceived by the patient as specifically related to SLE rather than to any other co-morbidity.
Few studies about the responsiveness of specific QoL instruments in SLE patients have been published. Furthermore, disease-specific questionnaires in SLE have only been developed in the past 5 years and data on their responsiveness are not yet fully available [11] . It is important to know the ability of these questionnaires to capture a change in SLE-related health status, which is crucial to their use in clinical trials. Moreover, as the course of SLE is characterized by a succession of flares and remission periods, knowing the responsiveness is a necessary precondition to the use of QoL questionnaires in clinical practice and epidemiological studies.
We aimed to estimate the responsiveness to change according to SLE patients' self-reported changes in health status of a generic [the 36-item Short Form Health Survey (SF-36)] and a specific HRQoL questionnaire [the Lupus Quality of Life questionnaire (LupusQoL)] in SLE and to determine the minimally important difference (MID) in the domain scores of these questionnaires (i.e. the minimal change that is important to patients).
Methods

Study design
We conducted a multicentre, prospective cohort study involving seven French university hospitals (Dijon, Besanç on, Reims, Nancy, Strasbourg, Metz and Pitié -Salpê triè re hospitals in Paris), which included two national reference centres for autoimmune diseases and SLE management. All of the clinicians involved in the study were members of the French lupus care network. We included consecutive SLE patients visiting these centres between March and November 2009 for their SLE care. The inclusion criteria were age between 18 and 75 years, SLE diagnosis according to the 1997 modified ACR classification criteria [12] and the ability to understand and complete self-reported questionnaires in French. The study was approved by the Research Ethics Committee CPP Est I and all of the participants gave written informed consent.
Data collection
Data were collected during four visits: one visit with the patient's usual SLE specialist at baseline (D0) and three postal surveys at 15 days (D15), 3 months (M3) and 6 months (M6) after the baseline visit. In addition to the recording of clinical data, which included the Safety of Estrogen in Lupus Erythematosus National Assessment (SELENA)SLEDAI and the SELENA-SLEDAI flare composite, patients had to return three postal questionnaires: the LupusQoL in French (LupusQoL-FR) [13] , the Systemic Lupus Activity Questionnaire (SLAQ, French validated version) [14, 15] and the SF-36 [16] .
This study was designed to validate LupusQoL-FR and document its psychometric properties for clinical research. Construct validity and testretest reliability analyses were carried out using data from the D0 (for construct validity) and D15 (for testretest validity) visits. These results have been described elsewhere [13] . The present report relies on data obtained at D0, M3 and M6 of the study.
The SELENA-SLEDAI is a validated SLE activity index comprising 24 items aggregated in nine organ systems. It was recorded at baseline. Clinical and laboratory data are required to complete the questionnaire. The score ranges from 0 to 105 points, with higher values related to higher disease activity. The SELENA-SLEDAI flare composite includes three elements: (i) the SELENA-SLEDAI score from 0 to 105; (ii) an assessment of new or worsening disease activity, medication changes and hospitalizations and (iii) the score for the physician's global assessment (PGA) visual analogue scale (VAS). This composite score makes it possible to distinguish between mild/moderate and severe flares between two assessments [17] .
The SLAQ is a patient self-assessed activity questionnaire based on items from a validated activity measure, the Systemic Lupus Activity Measure (SLAM). It has been validated in French [14] . The SLAQ includes SLAM items that are amenable to self-reporting along with 24 questions related to disease activity that are weighted and aggregated in a manner analogous to the scoring system used in the SLAM. The SLAQ score ranges from 0 to 48 [15] .
The SF-36 is a generic QoL questionnaire that has been widely validated and used in SLE. The items are grouped into eight domain scores: physical functioning (PF), role physical (RP), bodily pain (BP), global health (GH), vitality (VT), social functioning (SF), role emotional (RE) and mental health (MH). Domain scores can be collapsed to a physical component summary (PCS) and a mental component summary (MCS). Each score ranges from 0 to 100, with higher values representing better self-perceived HRQoL [16] .
The LupusQoL-FR is a lupus-specific HRQoL questionnaire consisting of 34 items grouped in eight domains: physical health, pain, planning, intimate relationships, burden to others, emotional health, body image www.rheumatology.oxfordjournals.org and fatigue. It was originally developed for Englishspeaking SLE patients from the UK. The validated French version showed good psychometric properties. We also demonstrated that the LupusQoL-FR items can be summarized into aggregated physical and mental domains [13] . Aggregated domains have not been validated in other versions of the LupusQoL.
LupusQoL/SF-36 domains that measure similar concepts are usually defined as follows: physical health/PF, pain/BP, burden to others/SF, emotional health/MH, fatigue/VT, physical aggregated/PCS and mental aggregated/MCS [5] .
Definition of anchors
We aimed to describe the amount of change in QoL measured by SF-36 and LupusQoL domain scores in patients with a worsening, improving or unchanging clinical status regarding various aspects of the disease. These aspects were approached by means of clinical anchors, i.e. specific items formulated to ask the patient about changes due to SLE that they had noted since the last visit. The variability and magnitude of change in each QoL domain score were compared between worsening, improving and unchanging patients to evaluate the responsiveness of SF-36 and LupusQoL.
The following specific anchors were used. A 7-point Likert scale describing the change in lupusrelated health status over 3 months. This item was formulated as follows: how would you describe the impact of lupus on your overall health since your last visit? The seven response options were À3, much improved; À2, moderately improved; À1, minimally improved; 0, the same; +1, minimally worse; +2, moderately worse and +3, much worse. Patients reporting À3 to À1 were classified as improving, while patients reporting +1 to +3 were classified as worsening. During the qualitative interviews conducted during the pretest phase of the LupusQoL-FR, we felt that the concept of disease activity was not explicit enough for many patients. For this reason we asked each patient to rate the impact of lupus on their overall health since their last visit. This wording was chosen in accordance with the pretest patients' group so as to be as consistent as possible with the definition of clinical activity and understandable by most of the patients. A 100 mm VAS was used with the following question: Please estimate the impact of your lupus on your health during the last 3 months by a vertical bar on the following line. The left part of the VAS was anchored by no impact and the right by the worst impact the patient could imagine. The change in VAS between two mail surveys was used to define worsening and improving patients. A difference of more than +1/2 S.D. of the whole sample between two assessments was considered an improvement, while À1/2 S.D. was considered worsening [18] .
A Likert scale from 0 (no problem) to 3 (severe problem) explored patient-reported symptoms. These items were extracted from the SLAQ. Patients with a difference of À1 or less for a given symptom between two assessments were classified as improving, while patients with a difference of +1 or more were classified as worsening. We calculated responsiveness for the following symptoms: fatigue, nasopharyngeal ulcers (sores in the mouth or nose), depression (feeling depressed), arthritis (pain or stiffness in joints) and alopecia (bald patches on the scalp or clumps of hair on the pillow). We chose these items because of their high frequency (fatigue, depression) and because they can be assessed objectively (mouth or nose ulcers, arthritis, alopecia).
Statistical analysis
We estimated the mean (S.D.) change and corresponding P-value (when comparing change to zero, i.e. unchanged) in each domain score of the SF-36 and LupusQoL by the mean of individual differences between two visits using mixed models for repeated measures. The change in a given domain score was included in the model as the dependent variable, while the status according to the anchor (worsening, unchanging or improving) was included as an independent variable. Patient effect was considered a random effect. A single mixed model was computed that considered two 3 month periods for each patient: D0M3 and M3M6.
The standardized response mean (SRM) statistic was then calculated in improving, unchanging and worsening patients according to each external anchor (Likert, VAS and symptoms). It aimed to evaluate the amount of change in a domain score by calculating the ratio between the mean change and the variability (estimated by the S.D.) of this change. SRM values of 0.300.50, 0.50.8 and >0.8 were interpreted as low, moderate and high responsiveness, respectively [19] . We estimated the SRM for improvement, no change and worsening separately in each SF-36 and LupusQoL domain score for each anchor. The SRM was expected to be at least moderate in LupusQoL and SF-36 domains in patients with improvement and worsening and <0.3 in patients reporting no change.
MID
The mean changes in LupusQoL and SF-36 domains were calculated in each category defined by the 7-point Likert scale (3, much improved; 2, moderately improved; 1, minimally improved; 0, the same; +1, minimally worse; +2, moderately worse and +3, much worse). The MID was determined as the mean change in LupusQoL and SF-36 domains observed in the minimally improved and the minimally worse Likert categories [2022] . We hypothesized that the MID scores would be different bidirectionally (improving and worsening). The statistical analysis was performed using SAS version 9.3 software (SAS Institute, Cary, NC, USA). The significance level was P < 0.05 for all tests.
Results
Patients' baseline characteristics
Patients' characteristics are described in Table 1 . We included 185 SLE patients in the study [162 women (88%) and 23 men (12%) with a mean age of 39.6 years (S.D. 10.5)].
The mean SELENA-SLEDAI score was 2.6 (S.D. 3.5, range 018). Twenty-five patients had presented a mild/moderate or severe flare as defined by the SELENA-SLEDAI composite flare index during the 6 months before the baseline visit. The patients were European Caucasian (74%), AfroCaribbean (9%), North African (13%) and Asian (3%). About 60% of the patients had an educational level equal to or higher than a French high school diploma. We analysed a total of 515 completed questionnaires (183 at D0, 164 at M3 and 168 at M6), accounting for 330 measures of change in QoL questionnaires (161 for the D0M3 period and 169 for the M3M6 period). According to the SF-36 domains, patients had a high PF score at baseline 
Responsiveness
The SRM, the mean variation in QoL domains and the corresponding significance for each anchor in worsening patients are shown in Table 2 . The results for improving patients are shown in Table 3 .
According to the Likert global anchor, 42 (26%) and 48 (28%) patients reported a worsening at M3 and M6, respectively. Ninety-eight (61%) and 81 (48%) patients reported no change and 21 (13%) and 40 (24%) patients reported an improvement at M3 and M6, respectively. The number of patients evaluated in each group for different anchors is reported in Tables 2 and 3 .
Global anchors
In the whole sample, the mean change in the VAS to estimate the impact of lupus was 4.8 (S.D. 23.6) on the 0100 scale. The cut-off for defining improving and worsening patients according to the VAS was thus 1/2 S.D., i.e. a variation of ± 11.8 in the mean VAS change.
Among visits with improving patients according to the VAS (n = 146), the domains of the LupusQoL that showed a significant improvement (P-value for mean improvement < 0.05 compared with worsening and stable patients) with low responsiveness (SRM < 0.5) were physical health, pain, fatigue and physical aggregated. Similarly the domains of the SF-36 that improved significantly (with low responsiveness) were RP, BP, SF, RE, PCS and MCS. Among visits with worsening patients (n = 53), the domains of the LupusQoL that showed a significant decrease (with low to moderate responsiveness) were physical health, planning, fatigue and physical aggregated. For the SF-36, a significant decrease was observed in the PF, RP, BP, MH, VT, GH and PCS domains, with low to moderate responsiveness.
Among visits with improving patients according to the global 7-point Likert scale (n = 89), all LupusQoL domains except for intimate relationship and all SF-36 domains except PF and GH showed a significant increase in domain scores, with low to moderate responsiveness. In worsening patients (n = 60), the decrease was significant in all SF-36 domain scores and in 7 of 10 LupusQoL domain scores (excluding burden to others, body image and fatigue). Responsiveness was low to moderate in these domains. No domain of the LupusQoL or SF-36 showed significant responsiveness in patients reporting no change according to the VAS or global Likert scale.
Symptom-based anchors
Responsiveness varied among symptoms. Most domain scores of both the LupusQoL and SF-36 showed significant responsiveness in patients with improving feeling depressed scores. The only exceptions were intimate relationship for the LupusQoL and GH for the SF-36. Worsening was associated with a significant decrease in LupusQoL emotional health and emotional aggregated scores only and in SF-36 SF, MH, VT and MCS scores.
RP, BP and RE SF-36 domains were responsive in patients with improving alopecia, while pain, emotional health and physical aggregated domains of the LupusQoL showed significant improvement with moderate responsiveness. In patients with worsening alopecia, both the LupusQoL physical health and SF-36 GH scores showed significant decreases. www.rheumatology.oxfordjournals.org For oral ulcers, improving patients showed a significant decrease in the LupusQoL pain and emotional health domains, but in none of the SF-36 domains. Among worsening patients, the LupusQoL intimate relationship and planning domains were significantly influenced by worsening oral ulcers, but no SF-36 domains were negatively influenced by this symptom.
For the fatigue item, improving patients reported a significant increase in all domain scores except for the LupusQoL intimate relationship score. In patients reporting worsening of their fatigue, the decrease was significant for the LupusQoL physical health, planning, fatigue and physical aggregated scores and the SF-36 PF, RP, BP, MH, VT and PCS scores.
In patients reporting improving arthritis, all LupusQoL scores except planning, intimate relationship and emotional health showed significant variation with low to moderate responsiveness. For the SF-36, the increase was significant in the PF, RP, BP and PCS domains. In patients with worsening arthritis, the increase was significant in all LupusQoL domains except body image and burden to others, with low to moderate responsiveness. Scores for the SF-36 domains MCS, RE, MH and SF did not show any significant decrease in these patients. In all other SF-36 domain scores, the decrease was significant with low to moderate responsiveness.
When SRMs of the SF-36 domains were compared with the corresponding LupusQoL domains, the SRMs for physical health, fatigue and physical aggregated were better than those for PF, VT and PCS in improving patients. In worsening patients, SF-36 domains had better responsiveness, depending on the clinical anchor (Fig. 1) .
MID
MIDs are shown in Table 4 . The MID for global improvement ranged from 1.1 to 9.2 and from 1.9 to 11.3 for LupusQoL and SF-36 domain scores, respectively (excluding LupusQoL aggregated domains and SF-36 MCS/PCS). In worsening patients, the MID ranged from 0.5 to 6.4 in LupusQoL domains and from 4.4 to 15.6 in SF-36 domains. 
Discussion
SLE is a complex disease that can involve all systems and organs. The diversity of potential presentations of SLE flares and subsequent treatments makes it difficult to define a standardized intervention to describe responsiveness. Because of this we chose to use data from a longitudinal observational cohort and to record patients' perceived symptoms to identify improving and worsening patients who were treated with standard care. The weakness of this approach is the potential recording of perceived symptoms that are due to conditions other than SLE or the risk of recording symptoms erroneously due to patients' misunderstanding the questionnaires. Nonetheless, when measuring QoL in clinical practice or in trials, one aims to capture the impact of the disease as perceived by the patient. For this reason, we thought that describing the change in the overall health status from the patient's perspective would be a good way to estimate the responsiveness of the target concept, i.e. the impact of SLE on the patient's perception of health. We used postal data collection to avoid patient's response being influenced by a physicianvisit. This may have resulted in slightly different responses compared with onsite data collection. However, we believe postal collection better reflects the patient's feelings. To our knowledge, this is the first article to describe the responsiveness of the LupusQoL questionnaire in SLE patients using this approach.
Touma et al. [23] recently described LupusQoL and SF-36 responsiveness according to clinical anchors (with a SLEDAI 2000-based definition of clinical activity) in 41 SLE patients assessed at monthly intervals for 1 year. No clear distinction was made in terms of SRM between the SF-36 and LupusQoL, but LupusQoL values were slightly better. Our patients were comparable in terms of disease activity, and we confirmed that both questionnaires were responsive in some domains using clinical anchors and an interval of 3 months. Although our data do not strongly support the idea that the LupusQoL is superior to the SF-36, some LupusQoL domains that are not explored by the SF-36 were responsive for some symptoms. Indeed, intimate relationship was responsive for Likert global health, oral ulcers, arthritis worsening and Likert global health improvement. Similarly, the body image score significantly increased in patients who reported improving depression, fatigue and arthritis. Moreover, some lupus-specific symptoms, for which changes were not captured by the SF-36, were associated with a significant variation in some LupusQoL domains. In fact, patients with worsening oral ulcers had a significantly lower score in the planning and intimate We clearly showed the absence of symmetry in the responsiveness between worsening and improving patients. This has already been suggested [21, 22] . Interestingly, the responsiveness of some SF-36 domains tended to exceed that of certain LupusQoL domains in worsening patients, while LupusQoL domains seemed to be more responsive in measuring improvement. It is possible that some of our patients reported worsening due to conditions that they did not consider to be caused by lupus. For example, in patients who reported worsening symptoms of feeling depressed, the responsiveness for comparable domains was better in the SF-36. We can hypothesize that some patients actually felt depressed because of an event or health condition that they did not link with SLE.
Our study provided the first results for LupusQoL MIDs. These values are of importance because they will help in interpreting the results of ongoing and future trials in terms of QoL. Our MID values for improvement in the SF-36 PCS and MCS (+2.3 and +2.2, respectively) are consistent with those of Colangelo et al. [22] , which showed a difference of +2.1 and +2.4 in the PCS and MCS, respectively. These results confirm the external validity of our study.
The first limitation of our study was that we recruited mostly Caucasian outpatients with inactive disease. This could limit the generalization of our results to other ethnic groups or active SLE patients. Nonetheless, during the 8 months of the study, 15% of the patients had a moderate to severe SLE flare and one-third had a SELENA-SLEDAI score 54, which corresponds to the proportion of flares in active SLE patients seen in the French national care network for lupus in clinical practice. Moreover, QoL questionnaires are intended to be used not only in clinical trials but also in epidemiological studies and in clinical practice as monitoring tools. Thus it is important to evaluate the responsiveness of these tools with regard to the perception of patients with low SLE activity, the most usual situation in clinical practice. In addition, the ethnic mix observed in our study was consistent with the French general population. Previous work conducted on the SF-36 and LupusQoL indicated content and construct validity and reliability across countries, ensuring their generalizability across international borders [7, 13, 16, 2427] . A 3 month interval between the assessments was chosen to limit missing questionnaires due to patients' weariness, despite the 4 week recall period of both QoL questionnaires. Nonetheless, the discordances between QoL questionnaires and anchor assessment may result in an underestimation of responsiveness of QoL questionnaires. It is thus unlikely that this limitation affected our significant findings regarding responsiveness. In addition, we did not use validated clinical disease activity measurements to define the variation in SLE activity. Thus self-reported symptoms in the SLAQ on arthritis or rashes may not be accurately attributed to SLE by patients. Nonetheless, the wording of the SLAQ items had been validated to define precise SLE-related symptoms, and an acceptable correlation has been shown with the SLAM clinical items. Furthermore, the use of a global clinical anchor is a reliable way to approach the concepts that we aimed to evaluate, i.e. patients' feelings about the impact of the disease. Finally, results concerning the LupusQoL aggregated domains are only suitable for the French version.
Conclusion
Both the SF-36 and LupusQoL were sufficiently responsive to evaluate QoL in SLE. As reported in other diseases [28] , specific and generic questionnaires seem to be complementary, as the generic questionnaire may be useful in capturing worsening symptoms, while the LupusQoL showed better responsiveness in improving patients, suggesting that these tools have to be used together. These results have to be confirmed in interventional studies. Moreover, the LupusQoL seems to be useful in some situations that are not explored by the SF-36, such as oral ulcers and alopecia.
Rheumatology key messages
. Both SF-36 and LupusQoL questionnaire are responsive to changes in health status according to patient perception in SLE. . The LupusQoL may be more responsive than the SF-36 in capturing changes in SLE patients with improving health status. . Minimally important differences for LupusQoL domains may be used to help interpret ongoing and future clinical trials in SLE.
